Haemonetics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Haemonetics and other ETFs, options, and stocks.

About HAE

Haemonetics Corp. engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, and Hospital. 

CEO
Christopher A. Simon
CEOChristopher A. Simon
Employees
3,023
Employees3,023
Headquarters
Boston, Massachusetts
HeadquartersBoston, Massachusetts
Founded
1971
Founded1971
Employees
3,023
Employees3,023

HAE Key Statistics

Market cap
3.95B
Market cap3.95B
Price-Earnings ratio
24.46
Price-Earnings ratio24.46
Dividend yield
Dividend yield
Average volume
720.66K
Average volume720.66K
High today
$85.83
High today$85.83
Low today
$83.45
Low today$83.45
Open price
$85.51
Open price$85.51
Volume
108.23K
Volume108.23K
52 Week high
$87.32
52 Week high$87.32
52 Week low
$47.32
52 Week low$47.32

Stock Snapshot

The current Haemonetics(HAE) stock price is $84.41, with a market capitalization of 3.95B. The stock trades at a price-to-earnings (P/E) ratio of 24.46.

On 2025-12-11, Haemonetics(HAE) stock moved within a range of $83.45 to $85.83. With shares now at $84.41, the stock is trading +1.2% above its intraday low and -1.6% below the session's peak.

Trading activity shows a volume of 108.23K, compared to an average daily volume of 720.66K.

The stock's 52-week range extends from a low of $47.32 to a high of $87.32.

The stock's 52-week range extends from a low of $47.32 to a high of $87.32.

HAE News

TipRanks 4h
Haemonetics downgraded to Neutral from Buy at Citi

Citi downgraded Haemonetics (HAE) to Neutral from Buy with a price target of $88, up from $77. The firm adjusted ratings and targets in the medical technology s...

Simply Wall St 3d
Haemonetics: Reassessing Valuation After a 55% Three-Month Share Price Surge

Haemonetics (HAE) has quietly rallied, with shares up roughly 23% over the past month and more than 55% in the past 3 months, prompting investors to recheck the...

Haemonetics: Reassessing Valuation After a 55% Three-Month Share Price Surge

Analyst ratings

82%

of 11 ratings
Buy
81.8%
Hold
18.2%
Sell
0%

People also own

Based on the portfolios of people who own HAE. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.